Jacquelyn Sturm, MD
Allergy & Immunology · Shiloh, ILNPI 1134311087
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,336 of the $9,013 with a category attached, or 81.4%. 29 manufacturers reported payments, led by Sanofi at 24.4% of the total. 2025 is the largest year on record at $3,082, 3.6 times the $857 reported in 2019.
Across 349 payments — averaging $25.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$2K
- AstraZeneca$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- GSK$789
- Regeneron Healthcare Solutions, Inc.$650
- CSL Behring$501
- plus $2K from 23 others
What the payments were for
- Consulting fees$1,47016%
- Food & beverage$7,33681%
- Education$2072%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 22 | $2,195 |
| AstraZeneca | 36 | $1,422 |
| Takeda Pharmaceuticals U.S.A., Inc. | 110 | $1,331 |
| GSK | 39 | $789 |
| Regeneron Healthcare Solutions, Inc. | 17 | $650 |
| CSL Behring | 26 | $501 |
| Optinose US, Inc. | 12 | $359 |
| Novartis | 14 | $253 |
| Amgen | 9 | $203 |
| Pfizer | 11 | $188 |
| Genentech USA, Inc. | 10 | $173 |
| Kaleo, Inc. | 8 | $133 |
| Octapharma USA, Inc. | 3 | $108 |
| Grifols USA, LLC | 5 | $95 |
| Sanofi-aventis U.S. LLC | 1 | $85 |
| Biocryst US Sales Co., LLC | 3 | $73 |
| Teva Pharmaceuticals USA, Inc. | 4 | $61 |
| Ionis Pharmaceuticals, Inc. | 2 | $55 |
| AbbVie | 2 | $55 |
| Azurity Pharmaceuticals, Inc. | 3 | $54 |
| Boehringer Ingelheim | 3 | $53 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $41 |
| Organon | 1 | $25 |
| ADMA Biomanufacturing LLC | 1 | $24 |
| Impel Pharmaceuticals Inc. | 1 | $22 |
| Merck | 1 | $19 |
| Phadia US Inc. | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Alk-abello, Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,013 in reported general payments places this provider in the 70th percentile of 161 allergy & immunology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 21 | $114,041 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 18 | $71,600 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 57 | $57,186 |
| Dupixent SyringeDupilumab | 12 | $45,248 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $11,343 |
| Arnuity ElliptaFluticasone Furoate | 23 | $5,460 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 44 | $4,466 |
| Wixela InhubFluticasone Propion/Salmeterol | 19 | $3,364 |
| Epinephrine | 21 | $3,091 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 15 | $2,727 |
| Azelastine Hcl | 76 | $2,201 |
| Ipratropium Bromide | 55 | $1,283 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 37 | $706 |
| Montelukast Sodium | 54 | $615 |
| Fluticasone Propionate | 21 | $501 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid, Cuvitru | $1,331 | $185,64239 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $789 | $73,989110 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 161 allergy & immunology providers in Illinois.
Other allergy & immunology in Shiloh
- Patrick WinShiloh$258K
- Dareen SiriNormal$1.5M
- Priya BansalSaint Charles$1.3M
- Anju PetersChicago$563K
- Giselle MosnaimChicago$331K
- Amanda SalihChicago$160K
- Rebecca HoffmanWilmette$160K
- Juanita MoraChicago$147K
- Sonali MajmudarAlgonquin$136K
- Zachary RubinElmhurst$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.